Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astellas Pharma Unsp/Adr (OP:ALPMY)

14.93 -0.08 (-0.53%)
Streaming Delayed Price Updated: 3:59 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 151,932
Open 15.17
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 15.01
Today's Range 14.87 - 15.18
52wk Range 8.370 - 16.95
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
Via Finterra
Topics Economy Initial Public Offering

Performance

YTD
+12.1%
+12.1%
1 Month
-2.9%
-2.9%
3 Month
+15.9%
+15.9%
6 Month
+30.1%
+30.1%
1 Year
+51.3%
+51.3%

More News

Read More
News headline image
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗
Via Benzinga
News headline image
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients ↗
Via Investor's Business Daily
News headline image
Why Is Taysha Gene Therapies Stock Falling Friday? ↗
Via Benzinga
News headline image
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗
Via Benzinga
News headline image
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗
Via Benzinga
News headline image
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗
Via Benzinga
News headline image
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo ↗
Via Benzinga
News headline image
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise ↗
Via Benzinga
News headline image
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact ↗
Via Benzinga
News headline image
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst ↗
Via The Motley Fool
News headline image
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗
Via Benzinga
News headline image
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗
Via Investor's Business Daily
News headline image
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data ↗
Via Benzinga
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
Via Talk Markets
News headline image
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗
Via Talk Markets
News headline image
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗
Via Benzinga
News headline image
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks ↗
Via Investor's Business Daily
News headline image
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study ↗
Via Benzinga
News headline image
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years ↗
Via The Motley Fool
News headline image
Why Is Seagen Stock Trading Higher Today? ↗
Via Benzinga
News headline image
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer ↗
Via Investor's Business Daily
News headline image
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? ↗
Via Benzinga
News headline image
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Via MarketBeat
Topics Economy

Frequently Asked Questions

Is Astellas Pharma Unsp/Adr publicly traded?
Yes, Astellas Pharma Unsp/Adr is publicly traded.
What exchange does Astellas Pharma Unsp/Adr trade on?
Astellas Pharma Unsp/Adr trades on the OTC Traded
What is the ticker symbol for Astellas Pharma Unsp/Adr?
The ticker symbol for Astellas Pharma Unsp/Adr is ALPMY on the OTC Traded
What is the current price of Astellas Pharma Unsp/Adr?
The current price of Astellas Pharma Unsp/Adr is 14.93
When was Astellas Pharma Unsp/Adr last traded?
The last trade of Astellas Pharma Unsp/Adr was at 03/06/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.